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Abstract
The elegance of fundamental and applied research activities have begun to reveal a myriad of spatial and temporal
alterations in downstream signaling networks affected by cell surface receptor stimulation including G protein–
coupled receptors and receptor tyrosine kinases. Interconnected biochemical pathways serve to integrate and dis-
tribute the signaling information throughout the cell by orchestration of complex biochemical circuits consisting of
protein interactions and covalent modification processes. It is clear that scientific literature summarizing results from
both fundamental and applied scientific research activities has served to provide a broad foundational biologic data-
base that has been instrumental in advancing our continued understanding of underlying cancer biology. This article
reflects on historical advances and the role of innovation in the competitive world of grant-sponsored research.
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The primary avenue for the financial support of cancer research
in the United States is from the National Institutes of Health (NIH).
The NIH, as part of its grant review process, has instituted the concept
of “innovation,” which must be included as part of the grant applica-
tion and review criteria. The goal of this change was to reward those
investigators who used innovative approaches in their grant application.
The difficulty in using innovation as a criterion for funding is that it
requires a grant application to have novel concepts, approaches, meth-
odologies, instrumentation, or interventions to be developed or used
by the applicant to support the overall research effort. Historically, a
requirement of innovation may have limited overall human progress.
For example, let us assume that we are in the period known as The
Age of Discovery, which ran from the early 15th century through
the early 17th century. During this time, Europeans were actively
undertaking exploration of the world and mapping the continents.
The Age of Discovery was a remarkable time for humanity as through
exploration, people expanded their understanding of the boundaries of
their known world. Would have a grant application to the government
at that time been considered innovative if the captain of a galley ship
proposed to go out and look for a new land? This, today, would be
called by grant reviewers a fishing expedition (no pun intended). How-
ever, notable progress could in fact be made with a single ship or a small
fleet of multimast ships each requiring a relatively small crew.
More recently, some areas of scientific inquiry require high-end
instrumentation to accomplish innovative research. Let us examine
for the moment the world of “big science.” The Large Hadron Collider
located in France is now completed and operational and is known as the
world’s largest and highest-energy particle accelerator. This instrument
was developed to investigate fundamental questions related to the phys-
ical laws of nature and the universe. This is perhaps the most expensive
scientific instrument ever built with a budget of 7.5 billion euros (US
$9 billion as of June 2010). The magnitude of this effort is truly un-
precedented, with 10,000 scientists working collectively making the
project the largest international collaborative research endeavor in his-
tory.Management of 10,000 geographically dispersed scientists pouring
over the data acquired and debating results and discussing interpreta-
tions thereof will be a major component to make the effort successful.
Who knows, perhaps the theoretically derived Higgs boson also known
as the “God particle” will be found to exist by this research effort (Higgs
PW [1964]. Phys Lett 12, 132; and Higgs PW [1964]. Phys Rev Lett
13, 508).
A slightly smaller scientific effort that is currently underway, requir-
ing another large piece of equipment, is the under-construction next-
generation space observatory called the James Webb Space Telescope
(JWST). This has currently cost US taxpayers $5 billion for prelaunch
construction of a telescope that detects objects in the infrared range of
the electromagnetic spectrum along with some capabilities in the visible
as well. This telescope has truly innovative technology including a
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6.5-m cryogenicmirror and is not without controversy (Billings L [2010].
Nature 467, 1028–1030). One of the goals of this telescope was to be
able to look farther back than the Hubble telescope all the way back
to the “cosmic dawn” some 500 million years after the Big Bang.
The JWST is anticipated to find the very first galaxies that formed in
the early universe and stars forming planetary systems that connect the
Big Bang to the MilkyWay. While the magnitude of the Large Hadron
Collider and the JWST efforts are monumental in overall costs relative
to the exploration undertaken in the Age of Discovery, nevertheless,
these pivotal efforts mark the quest of mankind to constantly expand
our understanding of the things around us.
The quest for improved knowledge is at its root based on not only
human curiosity but also in the drive to improve our quality of life.
The format of cancer research does not typically require massive
equipment and budgets that circumnavigate the globe. Basic biomed-
ical research often consists of a researcher conducting basic, untargeted
studies simply looking for answers to general questions. Results from
these types of studies add to the overall database of knowledge about
how living things work. Through basic fundamental research, one by
one, each piece of the complex cancer puzzle becomes available through
a large information database known as the peer-review literature. These
data, amassed by dedicated investigators, are used throughout the world
to develop rational and systematic approaches to further improve re-
search activities and clinical care. Research findings published by a single
scientist as well as local and disseminated research teams, whichmay also
include graduate students and postdoctoral fellows, contribute incre-
mental pieces of the overall puzzle. Dissemination of information from
geographically dispersed laboratories is accomplished at scientific meet-
ings and computer archive such as PubMed.com, which provide profi-
cient searching by relevant topic. Thus, research not only conducted in
broad general biology-based settings but also targeted research laborato-
ries tend to come together to improve opportunities for connecting the
bigger picture, eventually leading to finding a solution to a significant
scientific or clinical problem.
In cancer research, the pieces of the larger puzzle are increasingly
being discovered and put together in which elegant findings that reveal,
for example, that cellular responses to receptor stimulation can elicit a
myriad of spatial and temporal alterations in downstream signaling net-
works. The specificity and dynamic responses to external stimulation
are now known to be engaged through a limited number of cell surface
receptors including G protein–coupled receptors and receptor tyrosine
kinases. Biochemical pathways are used to transmit process, encode,
and integrate internal and external cellular signals using a myriad of
diverse and interconnected pathways. The regulatory mechanisms are
dependent on precise temporal control and spatial distribution of acti-
vated signal transducers, helper, and adapter molecules, which orches-
trate complex biochemical circuits of protein interactions and covalent
modification processes, which also serve to direct spatial relocation of
proteins within the cell.
Progress in cancer research requires both basic and clinical re-
search, and to further our understanding of cancer, scientists must
continue to gain a broader base of knowledge to add to our evolving
understanding of the specific cellular and molecular changes involved
in the initiation and progression of tumors. Thus, it becomes appar-
ent that we are all in this together and, like the interconnectedness of
cancer cell signaling, so too are most areas of scientific research, and
we can never quite tell which piece of the puzzle will provide the key
missing link to provide for a major advance. Basic biomedical and
clinical translational research such as supported by the NIH/National
Cancer Institute serves to provide the foundation for achieving inno-
vative advances in the diagnosis, treatment, and prevention of cancer.
Neoplasia continues to serve as a major publication as a rapid and
open-source conduit for the dissemination of relevant and timely in-
formation. Neoplasia publishes, on a monthly basis, numerous signif-
icant articles covering broad areas of cancer research including cell
and tumor biology, imaging, genetics, experimental therapeutics,
and clinical investigations (Table 1). Thus, the readership of Neopla-
sia is provided with a broad scope of information, thus serving to
provide many key pieces of the overall puzzle. The immediate avail-
ability of Neoplasia articles to the worldwide clinical cancer research
community is a key and unique feature of Neoplasia, and our primary
goal is to provide open access of all articles at the time of publication
through PubMed Central. This feature provides authors’ research find-
ings to the largest possible readership, thereby ensuring that articles
Table 1. Summary of Published Articles.
Subject 2009 2010 2011
Cancer genetics [3,8,17,20,31,42,67,75,
79,99,105,111,114,129–131]
[138,151–153,157,159,164,175,
176,185,206,223,230,234]
[274,275,277,278,286,309,
321,326,336,338,342,394]
Cell and tumor biology [2,7,10,13,16,19,21,23,
26,28–30,32,34,35,37,
38,40,41,47,49–51,53,
56,58,59,61,62,64,66,69,
72,75,78,80–83,85–87,91,93,
95,96,98,101,102,109,117,
119,120,122,126,128,132,134]
[139,141,142,147–149,155,
160–162,165,167,170,171,178,
180,181,184,186,188,189,191,
193–195,197,200,201,203,204,
207,210,212,214–216,218–222,
225–227,232,235,238,239,241]
[244,245,251–256,261,263,269,
271,279,280,282,287,289,291,
292,296–299,302–304,306,311,
312,314,316–318,320,325,327–329,
331,334,335,341,347,348]
Experimental therapeutics [4,9,11,15,36,48,55,60,71,73,
89,104,110,113,118,133,135]
[136,140,143,144,166,173,182,187,
190,199,209,211,228,233,236]
[242,243,245–247,249,250,257,259,
260,268,270,272,281,284,285,288,
290,293,295,300,301,322,323,332,
333,337,339,340]
Tumor immunology [1,22,27,44,45,57,65,70,76,77,94,
97,103,106,107,115,116,121,125]
[146,158,169,172,174,213,237] [266,276,305,308,313,319,324,330,
343,349]
Epidemiology and prevention [123] [196]
Cancer imaging [5,6,12,24,25,33,46,54,84,
88,90,100,127]
[150,205,217] [248,250,258,264,267,307,315]
Clinical investigations [14,18,39,43,52,63,68,92] [137,145,154,156,163,168,177,179,
183,192,198,202,208,229]
[273,346]
Animal models [108,112,124] [224,240] [265,283,310,344]
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published in Neoplasia will have the opportunity to make a significant
impact. Finally, as Editor and alongwith the Editorial Board, it has been
a gratifying to serve the greater cancer research community. We thank
the scientific groups who have entrusted the dissemination of their
research findings to our publications and we look forward to continue
to provide the broad cancer research community with many pieces to
the overall puzzle in the years ahead.
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